U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Media News - April 4, 2022 Category: Pharmaceuticals Source Type: news
Patients with Covid and flu double the risk of dying, say scientists
There have been calls for those hospitalised with the coronavirus to be routinely test for influenza after new research revealed an increased mortality rate for those with both conditionsSee all our coronavirus coverageCovid-19 patients who have been hospitalised should also be routinely tested for flu, researchers have said. The call was made after the publication of a paper in the medical journal theLancet that revealed having both conditions more than doubles the risk of a patient dying.Scientists also discovered that individuals who had contracted both Sars-CoV-2, the virus that causes Covid-19, and influenza viruses w...
Source: Guardian Unlimited Science - March 27, 2022 Category: Science Authors: Robin McKie Tags: Coronavirus Infectious diseases Medical research Science Immunology Health Biochemistry and molecular biology Source Type: news
CHMP recommends EU approval of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 yearsApproximately 40% of people with previously untreated DLBCL are not cured with the current standard of care and face a poor prognosis [1,2]Recommendation is based on pivotal data from the phase III POLARIX studyBasel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pol...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 yearsApproximately 40% of people with previously untreated DLBCL are not cured with the current standard of care and face a poor prognosis [1,2]Recommendation is based on pivotal data from the phase III POLARIX studyBasel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pol...
Source: Roche Media News - March 25, 2022 Category: Pharmaceuticals Source Type: news
Researchers show protein controls process that goes awry in Parkinson ’s disease
As scientists work toward finding a cure for Parkinson ’s disease, one line of research that has emerged focuses on mitochondria, the structures within cells that make energy. The health of those structures is maintained through a quality control system that balances two opposite processes: fission — one mitochondrion splitting in two — and fusion — two becoming one.When there ’s a problem with fission, that system is thrown out of balance. The consequences can include neurodegenerative diseases, such as Parkinson’s disease, and other serious conditions.For years, scientists have known that one particular prote...
Source: UCLA Newsroom: Health Sciences - March 24, 2022 Category: Universities & Medical Training Source Type: news
Potential glioblastoma treatment has roots in UCLA graduate research
A potential new treatment for glioblastoma that recently received approval for clinical trials not only was developed by three UCLA faculty members but also traces its roots back to 2005, when one of the researchers was a UCLA graduate student.The oral medication, a small molecule called ERAS-801, targets a rogue gene found in approximately 60% of people with the aggressive form of brain cancer. Developed by UCLA professors David Nathanson, Michael Jung and Dr. Timothy Cloughesy, the drug would provide a complement to existing treatments — surgery, radiation and chemotherapy.In December, ERAS-801 received a go-ahead fr...
Source: UCLA Newsroom: Health Sciences - March 15, 2022 Category: Universities & Medical Training Source Type: news
Fecal Microbiota-Based Screening Feasible for Pancreatic Cancer
WEDNESDAY, March 9, 2022 -- Fecal microbiota-based screening seems feasible for early detection of pancreatic ductal adenocarcinoma (PDAC), according to a study published online March 8 in Gut.
Ece Kartal, Ph.D., from the European Molecular Biology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 9, 2022 Category: Pharmaceuticals Source Type: news
Janssen Seeks Approval of a New Indication for IMBRUVICA ® (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma
BEERSE, BELGIUM, 8 March 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for IMBRUVICA® (ibrutinib) in combination with bendamustine and rituximab (BR) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation (ASCT).Ibrutinib is a once-daily Bruton's tyrosine kinase (BTK) inhibitor that is currently approved for patients with MCL who have received at least one prior lin...
Source: Johnson and Johnson - March 8, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
The secret to longevity? Ask a yellow-bellied marmot
This study is the closest scientists have gotten to showing that biological processes involved in hibernation are important contributors to their longer-than-expected life span based on their body weight,” said Pinho, now a researcher with the nonprofit Institute of Ecological Research’s Lowland Tapir Conservation Initiative in Brazil.“The fact that we are able to detect this reduced aging during hibernation in a wild population means the effect of hibernation on slowing aging is really strong,” said Blumstein, a member of the UCLA Institute of the Environment and Sustainability and a senior author of the study....
Source: UCLA Newsroom: Health Sciences - March 7, 2022 Category: Universities & Medical Training Source Type: news
NLM Technical Bulletin, Mar-Apr 2022, NCBI Virtual Workshop Series: Exploring 3D Molecular Structures with NCBI Tools
The National Center for Biotechnology Information (NCBI) is pleased to announce an upcoming virtual workshop that is now accepting applications. The NCBI Education Team invites you to apply and share this opportunity with any colleagues who may be interested. Our NCBI Virtual Workshops series was developed last fall to expand our reach to individuals who use NCBI resources for biological/biomedical research, science education, and clinical application efforts. Please review the workshop description to understand the intended audience. Each workshop will accept a limited number of participants to facilitate the best possibl...
Source: NLM Technical Bulletin - March 1, 2022 Category: Databases & Libraries Source Type: news
Bacterial and archaeal genomes with GO terms in RefSeq!
RefSeq prokaryotic genomes and proteins are now annotated with Gene Ontology (GO) terms. Over the years we have received many requests to add GO terms to the annotations we provide. We heard you! We are embarking on this adventure and starting to place terms from the Biological Process, Molecular Function and Cellular Component ontologies to … Continue reading Bacterial and archaeal genomes with GO terms in RefSeq! →
The post Bacterial and archaeal genomes with GO terms in RefSeq! appeared first on NCBI Insights. (Source: NCBI Insights)
Source: NCBI Insights - February 24, 2022 Category: Databases & Libraries Authors: NCBI Staff Tags: What's New NCBI Prokaryotic Genome Annotation Pipeline (PGAP) Protein Family Model RefSeq Source Type: news
Knowing the Origins of COVID-19 Won ’t Change Much
Over two years since the first cases started appearing in Wuhan, China, there is much we don’t know about the origins of SARS-CoV-2, the virus causing COVID-19. But a quick resolution to that question is possible: scientists could find bats in a cave somewhere in China or in southeast Asia and trace a chain leading from those bats to the COVID-19 outbreak in Wuhan. Realistically, however, recent history offers little promise for this to happen quickly. For example, about 14 years elapsed between the identification of HIV as the virus that caused AIDS and a demonstration of its modern transition to humans from a speci...
Source: TIME: Health - February 23, 2022 Category: Consumer Health News Authors: Robert C. Gallo and Dean T. Jamison Tags: Uncategorized COVID-19 Source Type: news
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
WHO ’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countriesSince the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in global treatment guidelinesTwelfth Roche medicine or test to be prequalified Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confi...
Source: Roche Media News - February 22, 2022 Category: Pharmaceuticals Source Type: news
Geisel Professors Dunlap and Loros Receive Pioneer Awards from Society for Research on Biological Rhythms
Jennifer Loros, PhD, a professor of Biochemistry and Cell Biology and of Molecular Systems Biology, and Jay Dunlap, PhD, the Nathan Smith Professor of Molecular and Systems Biology and of Biochemistry and Cell Biology, at Dartmouth’s Geisel School of Medicine have both received the Pioneer Program Award from the Society for Research on Biological Rhythms. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - February 17, 2022 Category: Hospital Management Authors: Timothy Dean Tags: News Jay Dunlap Jennifer Loros Source Type: news
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
WHO ’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countriesSince the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in global treatment guidelinesTwelfth Roche medicine or test to be prequalified Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confi...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
